- Home
- LVO vs PROK Comparison
LVO vs PROK Comparison
Compare LVO & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- PROK
- Stock Information
- Founded
- LVO 2009
- PROK 2015
- Country
- LVO United States
- PROK United States
- Employees
- LVO N/A
- PROK N/A
- Industry
- LVO Restaurants
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LVO Consumer Discretionary
- PROK Health Care
- Exchange
- LVO Nasdaq
- PROK Nasdaq
- Market Cap
- LVO 82.1M
- PROK 85.5M
- IPO Year
- LVO N/A
- PROK N/A
- Fundamental
- Price
- LVO $0.65
- PROK $2.82
- Analyst Decision
- LVO Strong Buy
- PROK Buy
- Analyst Count
- LVO 1
- PROK 5
- Target Price
- LVO $1.50
- PROK $6.25
- AVG Volume (30 Days)
- LVO 753.1K
- PROK 37.5M
- Earning Date
- LVO 08-12-2025
- PROK 08-12-2025
- Dividend Yield
- LVO N/A
- PROK N/A
- EPS Growth
- LVO N/A
- PROK N/A
- EPS
- LVO N/A
- PROK N/A
- Revenue
- LVO $114,405,000.00
- PROK $306,000.00
- Revenue This Year
- LVO N/A
- PROK $105.79
- Revenue Next Year
- LVO $18.93
- PROK N/A
- P/E Ratio
- LVO N/A
- PROK N/A
- Revenue Growth
- LVO N/A
- PROK N/A
- 52 Week Low
- LVO $0.55
- PROK $0.46
- 52 Week High
- LVO $1.82
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- LVO 38.18
- PROK 53.07
- Support Level
- LVO $0.64
- PROK $2.56
- Resistance Level
- LVO $0.72
- PROK $3.04
- Average True Range (ATR)
- LVO 0.06
- PROK 0.43
- MACD
- LVO -0.01
- PROK -0.16
- Stochastic Oscillator
- LVO 9.58
- PROK 14.94
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.